The company's artificial intelligence (AI) technology for structure-based small molecule drug discovery, AtomNet, is currently being used in 19 countries. Eli Lilly and Atomwise have joined forces to use AI in drug discovery . They will collaborate to test up to 10 development targets developed by Eli Lilly . The partnership will use Lilly ’s AI - driven structure - based small molecule drug discovery technology AtomNet , which is already being used in 19 countries . As part of the deal Atomwise will earn up to $ 1 m for discovery milestones and up to $ 550 m for investment in development and testing . CEO Abe Heifets said the technology could screen billions of compounds faster than existing screening systems , with up to 10,000 times greater accuracy .
Eli Lilly and Atomwise have joined forces to use AI in drug discovery . They will collaborate to test up to 10 development targets developed by Eli Lilly . The partnership will use Lilly ’s AI - driven structure - based small molecule drug discovery technology AtomNet , which is already being used in 19 countries . As part of the deal Atomwise will earn up to $ 1 m for discovery milestones and up to $ 550 m for investment in development and testing . CEO Abe Heifets said the technology could screen billions of compounds faster than existing screening systems , with up to 10,000 times greater accuracy .